PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
8 hedge funds and large institutions have $96M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
5% less capital invested
Capital invested by funds: $101M → $96M (-$5.33M)
20% less funds holding
Funds holding: 10 → 8 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$607K |
| 2 |
Millennium Management
New York
|
-$41.3K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$13K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBA
1
Baker Bros. Advisors
New York
| $64.9M | – | – | – |
|
|
BI
2
BVF Inc
San Francisco,
California
| $13.1M | – | – | – |
|
|
NMC
3
NEA Management Company
Timonium,
Maryland
| $13.1M | – | – | – |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $2.52M | – | – | – |
|
|
DG
5
Delek Group
Herzliya,
Israel
| $1.47M | – | – | – |
|
|
6
Millennium Management
New York
| $874K | -$41.3K | -194 | -4% |
|
|
7
UBS Group
Zurich,
Switzerland
| $25K | -$9.8K | -46 | -28% |
|
|
EDRH
8
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $12K | – | – | – |
|
|
9
Jane Street
New York
| – | -$607K | -2,734 | Closed |
|
|
10
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$13K | -60 | Closed |
|
PHXM Hedge Fund Activity: Q1 2018 in Review
8 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q1 2018, worth a combined $96M — down 5.3% from $101M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHXM and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Jane Street, exiting entirely with an estimated $607K sold.
- 8 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q1 2018, down from 10 in Q4 2017.
- Funds reported $96M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q1 2018, down 5.3% quarter-over-quarter.
- 0 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q1 2018 and 2 closed out, a net change of -2 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q1 2018 was Jane Street, an estimated $607K sold.
Based on aggregated 13F filings for Q1 2018.